Mark C. McKenna is a luminary biotech entrepreneur, executive and director with a track record of delivering exceptional results for investors and patients.

Mr. McKenna served as Chairman, President and CEO of Prometheus Biosciences from 2019 through the company’s acquisition by Merck for $10.8 billion in June 2023. Under his leadership, Prometheus raised more than $1 billion in private and public financing, was the top performing biotech IPO of 2021, created the first precision therapeutics for immune-mediated diseases, delivered industry-best results in Phase 2, and was acquired by Merck in the largest buyout of a pre-Phase 3 asset to date.

Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of Salix Pharmaceuticals, where he revitalized the gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2 billion while enhancing operating margins.

Earlier, Mr. McKenna served at Bausch + Lomb for more than a decade, most recently as SVP and General Manager of the US Vision Care business where he significantly grew revenue by 22% CAGR in an otherwise flat market. He began his career at Johnson & Johnson and held several positions of increasing responsibility.

He currently serves as the Chairman of Apogee Therapeutics, Inc. (Nasdaq: APGE), and is a board member of Spyre Therapeutics, Inc. (Nasdaq: SYRE) and New Amsterdam Pharma (Nasdaq: NAMS). In addition, Mr. McKenna is a Venture Partner at ARCH and a Senior Advisor to Fairmount Funds. Mr. McKenna was Ernst & Young Entrepreneur of the Year in 2023, and holds a B.S. in marketing from Arizona State University and an M.B.A from Azuza Pacific University.